StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q2 2026
138
Period ended Jun 30, 2026
Change on a year earlier
+7.0%
129 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCapvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026138+7.0%Form 10-Q (filed 2026-08-07) ↗
Q1 2026Mar 31, 2026118+11.3%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 2025258+426.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025238+406.4%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025129–Form 10-Q (filed 2026-08-07) ↗
Q1 2025Mar 31, 2025106–Form 10-Q (filed 2026-05-04) ↗
Q4 2024Dec 31, 202449–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202447–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20240–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20240–Form 10-Q (filed 2025-05-02) ↗

Cite this data

StockData. (2026). Merck Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_capvaxive_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.